BONE CANCER PAIN STUDY
Fully Funded Clinical Trial for Canine Appendicular Osteosarcoma

Study Title: Open-Label, Phase-2 Trial of NV-01 for Pain Palliation in Dogs with Osteosarcoma

Purpose of the study: New forms of treatment to control osteosarcoma (OS) bone pain are desperately needed. It has been shown that nerves to normal bone and bone tumors are influenced by nerve growth factor (NGF). In mice, bone cancer pain can be alleviated by administration of drugs that inhibit NGF without altering normal nerve function. It has also been shown that OS in dogs expresses the receptor for NGF. NV-01 is an antibody against NGF that blocks the activity of NGF. This clinical trial will evaluate the benefit of the NV-01 antibody therapy for the treatment of bone cancer pain in dogs with appendicular OS.

Inclusion Criteria:
- Presumed appendicular OS based upon radiographs or other diagnostics (including cytology or histopathology)
- Dogs must have favorable performance status
- Dogs must demonstrate clinical lameness, but still be using the limb during ambulation
- Owners must consent to a postmortem examination (autopsy) at the time their pet dies or is euthanized

Exclusion Criteria:
- NO pathologic fractures at the tumor site or non-weight bearing lameness
- NO previous treatment with radiation therapy, chemotherapy, or bisphosphonates
- NO homeopathic/alternative therapies while on study

Diagnostics:
- Screening bloodwork and urinalysis
- Thoracic and limb radiographs
- Potential cytology or histopathology

Treatment: Dogs will be treated with NV-01 antibody every 21 days for 9 weeks. At the end of 9 weeks, dogs will be re-evaluated and can stay on trial indefinitely, as long as pain is adequately controlled per owner and clinician assessment and there is no objective evidence of disease progression.

Compensation: The study will cover costs associated with the trial, except for diagnostics required to determine eligibility which include initial appointment fee, blood work, urinalysis, and imaging. At the conclusion of 9 weeks of study, should NV-01 be ineffective for alleviating bone cancer pain, a $750.00 credit will be applied to your dog’s account at the University of Illinois Veterinary Teaching Hospital, which can be used for alternative treatments such as radiation therapy, surgery, and pain medications.

Contact information: Please feel free to call Rebecca Kamerer 217-300-6453 to refer a patient or for any additional information. Referring veterinarian and client calls are welcome. Owners may schedule appointments by calling 217-333-5300.